Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ben Bronstein Insider Profile
4 Followers
Ben Bronstein, Director at Aldeyra Therapeutics, holds 28.25K shares in Aldeyra Therapeutics (Ticker: ALDX). Most recently, Ben Bronstein Bought $9,604 shares of Aldeyra Therapeutics on Jun 29, 2023 for an estimated value of 5.28K.
Profitable Transactions
3 out of 4 Profitable Transactions
Average Return
+8.30%
Average return per transaction
Time Frame
Compare to
Insider Roles
Director
Roles that Ben Bronstein holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Buy
Date:Feb 21, 2017 - Feb 21, 2018
Return:+48.50%
The most profitable trade made by Ben Bronstein
Ben Bronstein's Trading History
List of latest transactions for each holding click on a transaction to see Ben Bronstein's performance on stock
You May Also Like
Ben Bronstein insider profile FAQ
What is the percentage of profitable transactions made by Ben Bronstein?
The percentage of profitable transactions made by Ben Bronstein is 75%.
What is the average return per transaction made by Ben Bronstein?
The average return per transaction made by Ben Bronstein is 8.30%.
What stocks does Ben Bronstein hold?
Ben Bronstein holds: ALDX stocks.
What was Ben Bronstein’s latest transaction?
Ben Bronstein latest transaction was an Informative Buy of $5.28K.
What was Ben Bronstein's most profitable transaction?
Ben Bronstein’s most profitable transaction was an Informative Buy of ALDX stock on February 21, 2017. The return on the trade was 48.50%.
What is Ben Bronstein's role in Aldeyra Therapeutics?
Ben Bronstein's role in Aldeyra Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.